| 2601 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome-Eb1 |
Hematology |
2023 |
Standard Therapy |
Poland |
48 |
| 2602 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
73 |
| 2603 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
76 |
| 2604 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2605 |
Apheresis |
Allogeneic |
Myelodysplastic Syndromes (MDS) |
Hematology |
2023 |
Standard Therapy |
Poland |
5 |
| 2606 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
65 |
| 2607 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
56 |
| 2608 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2609 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
69 |
| 2610 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
61 |
| 2611 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2612 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2613 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
50 |
| 2614 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
54 |
| 2615 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2023 |
Standard Therapy |
Poland |
60 |
| 2616 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2617 |
Apheresis |
Autologous |
No Data |
Hematology |
2023 |
Standard Therapy |
Germany |
69 |
| 2618 |
Apheresis |
Autologous |
No Data |
Hematology |
2023 |
Standard Therapy |
Germany |
53 |
| 2619 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
50 |
| 2620 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
23 |
| 2621 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
39 |
| 2622 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
2 |
| 2623 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
52 |
| 2624 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2023 |
Standard Therapy |
Poland |
61 |
| 2625 |
Apheresis |
Autologous |
No Data |
Hematology |
2023 |
Standard Therapy |
Germany |
60 |
| 2626 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
71 |
| 2627 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
44 |
| 2628 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
72 |
| 2629 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
66 |
| 2630 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
33 |
| 2631 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
42 |
| 2632 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2633 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
19 |
| 2634 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
54 |
| 2635 |
Apheresis |
Autologous |
Nonseminoma, Relapse |
Hematology |
2023 |
Standard Therapy |
Germany |
48 |
| 2636 |
Apheresis |
Allogeneic |
Orofacial Myofunctional Disorders (OMDS), Primary Myelofibrosis (PMF) |
Hematology |
2023 |
Standard Therapy |
Poland |
69 |
| 2637 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
60 |
| 2638 |
Apheresis |
Allogeneic |
Other Immune System |
Hematology |
2023 |
Standard Therapy |
Poland |
71 |
| 2639 |
Apheresis |
Allogeneic |
Other Malignancy |
Hematology |
2023 |
Standard Therapy |
Poland |
49 |
| 2640 |
Apheresis |
Allogeneic |
Other Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
56 |
| 2641 |
Apheresis |
Allogeneic |
Other Non-Malignant Disease |
Hematology |
2023 |
Standard Therapy |
Poland |
70 |
| 2642 |
Apheresis |
Allogeneic |
Paroxysmal Nocturnal Hemoglobinuria (Pnh) |
Hematology |
2023 |
Standard Therapy |
Poland |
36 |
| 2643 |
Apheresis |
Allogeneic |
Peripheral T-Cell Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
47 |
| 2644 |
Apheresis |
Autologous |
Plasma Cell Leukemia |
Hematology |
2023 |
Standard Therapy |
Germany |
70 |
| 2645 |
Apheresis |
Autologous |
Plasma Cell Leukemia |
Hematology |
2023 |
Standard Therapy |
Germany |
56 |
| 2646 |
Apheresis |
Autologous |
Plasmacytoma |
Hematology |
2023 |
Standard Therapy |
Germany |
63 |
| 2647 |
Apheresis |
Allogeneic |
Post Therapeutic Myelodysplastic Syndrome /Acute Myelogenous Leukemia After Chronic Lymphocytic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
60 |
| 2648 |
Apheresis |
Allogeneic |
Post–Polycythemia Vera Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
38 |
| 2649 |
Apheresis |
Allogeneic |
Pra B-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
20 |
| 2650 |
Apheresis |
Allogeneic |
Pre-B-Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
41 |
| 2651 |
Apheresis |
Allogeneic |
Pre-B-Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
61 |
| 2652 |
Apheresis |
Allogeneic |
Pre-B-Acute Myelogenous Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
11 |
| 2653 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2023 |
Standard Therapy |
Germany |
63 |
| 2654 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2023 |
Standard Therapy |
Germany |
73 |
| 2655 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Germany |
70 |
| 2656 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2657 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2658 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
31 |
| 2659 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2660 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Germany |
46 |
| 2661 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2023 |
Standard Therapy |
Poland |
68 |
| 2662 |
Apheresis |
Allogeneic |
Relapsed B-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
11 |
| 2663 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
55 |
| 2664 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
58 |
| 2665 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
36 |
| 2666 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
62 |
| 2667 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
9 |
| 2668 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
28 |
| 2669 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2023 |
Standard Therapy |
Poland |
17 |
| 2670 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2023 |
Standard Therapy |
Poland |
1 |
| 2671 |
Apheresis |
Allogeneic |
Systemic Mastocytosis |
Hematology |
2023 |
Standard Therapy |
Poland |
63 |
| 2672 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
15 |
| 2673 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
28 |
| 2674 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
12 |
| 2675 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
65 |
| 2676 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2023 |
Standard Therapy |
Poland |
18 |
| 2677 |
Apheresis |
Allogeneic |
T-Cell Lymphoma |
Hematology |
2023 |
Standard Therapy |
Poland |
65 |
| 2678 |
Apheresis |
Allogeneic |
Thalassemia Major |
Hematology |
2023 |
Standard Therapy |
Poland |
2 |
| 2679 |
Apheresis |
Allogeneic |
Treatment-Related Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
67 |
| 2680 |
Apheresis |
Allogeneic |
Treatment-Related Myelodysplastic Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
64 |
| 2681 |
Apheresis |
Allogeneic |
Wiskott-Aldrich Syndrome |
Hematology |
2023 |
Standard Therapy |
Poland |
2 |
| 2682 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2022 |
Experimental Therapy |
Poland |
15 |
| 2683 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2022 |
Experimental Therapy |
Poland |
6 |
| 2684 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2022 |
Experimental Therapy |
Poland |
12 |
| 2685 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2022 |
Experimental Therapy |
Poland |
7 |
| 2686 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2022 |
Experimental Therapy |
Poland |
2 |
| 2687 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease; Acute Lymphoblastic Leukemia |
Hematology |
2022 |
Experimental Therapy |
Poland |
4,6 |
| 2688 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease; Acute Lymphoblastic Leukemia |
Hematology |
2022 |
Experimental Therapy |
Poland |
5,4 |
| 2689 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2022 |
Experimental Therapy |
Poland |
42,8 |
| 2690 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2022 |
Experimental Therapy |
Poland |
60,5 |
| 2691 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2022 |
Experimental Therapy |
Poland |
69,7 |
| 2692 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2022 |
Experimental Therapy |
Poland |
70,5 |
| 2693 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2022 |
Experimental Therapy |
Poland |
54,2 |
| 2694 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2022 |
Experimental Therapy |
Poland |
76,1 |
| 2695 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2022 |
Experimental Therapy |
Poland |
6,3 |
| 2696 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2022 |
Experimental Therapy |
Poland |
9,1 |
| 2697 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2022 |
Experimental Therapy |
Poland |
3,9 |
| 2698 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2022 |
Experimental Therapy |
Poland |
7,3 |
| 2699 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2022 |
Experimental Therapy |
Poland |
7,8 |
| 2700 |
Cord Tissue |
Allogeneic – Unrelated |
Autism |
Neurology |
2022 |
Experimental Therapy |
Poland |
7 |